CDKN2A and lung cancer: RARβ, CDKN2A, DAPK, RASSF1A and MGMT were examined, and the analysis showed that a patient having methylation of just one gene had an odds ratio of 5.08, meaning they were approximately five times likely to have lung cancer than patients without any methylated genes.